Combination therapy with nogapendekin alfa inbakicept and BCG achieved a 3-year DSS rate of 96% in BCG-unresponsive NMIBC ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy ...

The phase 3, open-label, single arm BOND-003 trial also evaluated cretostimogene in cohort P with papillary-only high-grade NMIBC who failed prior BCG therapy.

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its ...

Katie Tombs was just days away from a once-in-a-lifetime trip around the world when a chance discovery revealed a devastating ...

Popular rock frontman Michael Sweet of Stryper gave his fans an update on his cancer battle on Christmas Eve. The 62-year-old ...

The past decade has seen a major shift in how thyroid cancer is diagnosed and managed. R. Michael Tuttle, MD, chief of endocrinology service at Memorial Sloan Kettering Cancer Center and professor of ...

The higher the deduction, the lower the payout ratio in insurance claims, which often leads the family to bear significant ...

Valeria Alarcón has turned what she calls the “pain points” in her life into something much bigger. A native of Ecuador, ...

When exhaustion and anxiety began plaguing Rachel Christensen's daily life, she assumed it was just her busy lifestyle. But ...

Gene Holdings Inc. rises on 62% CR rate in Phase 2 NMIBC trial. Click to learn about ENGN and its gene delivery tech, market ...

Symptoms of stage 3 RCC vary; some patients experience blood in the urine, flank pain, fatigue, weight loss, or a palpable ...